Previous 10 | Next 10 |
Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™ Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates seen in SERENITY I and II BXCL501 was well tolerated and demo...
2023-05-22 03:50:58 ET Summary BioXcel Therapeutics' stock rose 47% despite challenges in drug adoption and a prior "Sell" recommendation. In Q1 2023, the financials revealed a net loss of $52.8 million, attributable to higher R&D and SG&A costs, with only $206,000 in reve...
BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically Planning Phase 2 human proof-of-concept study to evaluate BXCL501 as a potential adjunctive treatment in MDD Data further supportive of ongoing clinical programs evaluating BXCL501...
2023-05-11 16:18:07 ET Summary BioXcel Therapeutics, Inc. is currently in exciting times, awaiting very important clinical trial results in the coming weeks. The recently released BioXcel Therapeutics first-quarter results provided a low revenue figure for IGALMI, however, the mar...
2023-05-11 15:13:59 ET Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite , for instance, edged higher by nearly 3% during the first thr...
2023-05-08 16:54:00 ET Shares of the commercial-stage biopharma BioXcel Therapeutics (NASDAQ: BTAI) were up by 10.3% on heavy volume as of 3:29 p.m. ET Monday afternoon. The big gain came after the drugmaker reported 2023 first-quarter earnings ahead of the opening bell this mor...
2023-05-08 14:48:08 ET BioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Conference Call May 8, 2023 08:00 ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Rob Risinger - Chief Medical Officer, Neuroscience Matt Wiley - Chief Commercia...
2023-05-08 08:17:24 ET MDJM ( MDJH ) -27% . Catalent ( CTLT ) -20% on rejecting TRC Capital's tender offer for shares BioXcel Therapeutics ( BTAI ) -15% after Q1 earning release . Baosheng Media Group Holdings ( BAOS ) -13% . Minim (...
2023-05-08 07:02:06 ET BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q1 GAAP EPS of -$1.84 misses by $0.18 . Revenue of $0.21M misses by $0.11M . For further details see: BioXcel Therapeutics GAAP EPS of -$1.84 misses by $0.18, revenue of $0.21M mi...
IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote Top-line data from pivotal SERENITY III Phase 3 trial (Part 1) for BXCL501 in...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...